ACOG
Alpha Cognition IncKey Statistics
About Alpha Cognition Inc
Alpha Cognition Inc. is a forward-thinking biopharmaceutical company dedicated to pioneering innovative therapies for neurodegenerative conditions, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, targets cognitive enhancement, addressing significant unmet needs within the aging demographic. By harnessing a proprietary neuroscience platform and robust research and development initiatives, Alpha Cognition is positioned to drive advancements in patient care. As the company advances its clinical pipeline and explores additional therapeutic avenues, it represents a compelling investment prospect for institutional investors seeking exposure to transformative innovations in the healthcare sector.
Fundamentals
| Revenue (TTM) | $10.83M |
| Gross Profit (TTM) | $9.47M |
| EBITDA | $-27.27M |
| Operating Margin | -229.10% |
| Return on Equity | -51.70% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.57 |
| Book Value | $2.64 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 11.77 |
| EV/Revenue | 7.37 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.70% |
| Shares Outstanding | $21.77M |
| Float | $12.12M |
| % Insiders | 10.44% |
| % Institutions | 53.55% |
Historical Volatility
Volatility is currently expanding